drugset / Trial / NCT05345002
All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma
Phase 2
Recruiting
55 enrolled
Stephen Bagley, MD, MSCE
Abramson Cancer Center at Penn Medicine · collabIncyte Corporation · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase II study of the combination of All-Trans Retinonic Acid (ATRA) and PD-1 inhibition (Retifanlimab) in patient with recurrent IDH-mutant glioma. The Sponsor-Investigator hypothesizes that the proposed regimen will be safe and stimulate a robust anti-tumor immune response.
Timeline
- Start
- 2022-11-16
- Primary completion
- 2027-06-01
- Completion
- 2028-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Retifanlimab | Monoclonal antibody | 500 mg | Intravenous |
| Subject | Tretinoin | Small molecule | 45 mg/m2 | Oral |